Experimental combo aims to outsmart resistant lung cancer
NCT ID NCT05401110
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This early-phase trial tests whether adding carotuximab to the standard drug osimertinib is safe for people with advanced EGFR-mutated non-small cell lung cancer. About 60 participants whose cancer has progressed on prior treatments will receive both drugs. The main goal is to find the best dose and check for side effects, while also seeing if the combination can shrink tumors or delay progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Cancer at Beverly Hills (THO)
RECRUITINGBeverly Hills, California, 90211, United States
Contact
-
Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC
RECRUITINGTorrance, California, 90505, United States
Contact
-
Cedars-Sinai Cancer at SOCC
RECRUITINGLos Angeles, California, 90048, United States
Contact
-
Cedars-Sinai Cancer at The Angeles Clinic and Research Institute
RECRUITINGLos Angeles, California, 90025, United States
Contact
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Osimertinib and carotuximab
What this could lead to
If this works, it could offer a new treatment option for people with EGFR-mutated lung cancer whose current therapy stops working.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not yet proven to work. The combination may cause side effects or not shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.